share_log

双鹭药业(002038.SZ):GLP-1两个项目临床试验中都未单独进行减肥临床研究

Shuanglu Pharmaceutical (002038.SZ): No separate weight loss clinical studies were conducted in the GLP-1 clinical trials

Gelonghui Finance ·  Nov 20, 2023 17:08

On November 20, Gelonghui, on the investor interactive platform, some investors asked Shuanglu Pharmaceutical (002038.SZ), “Has the GLP-1 project currently being developed approved for obesity and overweight indications? “Don't answer by using methods such as GLP1 for lowering sugar and weight loss, etc.” The company replied that in the clinical trials of the company's GLP-1 projects, no separate weight loss clinical studies were conducted, but weight changes were observed as secondary efficacy indicators, and no marketing application has been submitted so far.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment